The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. This year’s metric has recorded a Price increase of 5.80%. However, over the past six months, we’ve seen a weaker performance of 17.65%. The price of ABCL fallen by 3.33% over the last 30 days. And in the last five days, it has fallen by -8.28%.
AbCellera Biologics Inc experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $5.46 on 02/20/24, while the lowest price for the same period was registered at $2.34 on 09/10/24.
52-week price history of ABCL Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. AbCellera Biologics Inc’s current trading price is -43.22% away from its 52-week high, while its distance from the 52-week low is 32.76%. The stock’s price range during this time has been between $2.34 and $5.46. The trading volume for the Healthcare sector company’s shares reached about 3.0 million for the day, which was lower than the average daily volume of 3.13 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
AbCellera Biologics Inc (ABCL) has experienced a quarterly rise of 14.81% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 915.63M and boasts a workforce of 586 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.87, with a change in price of +0.35. Similarly, AbCellera Biologics Inc recorded 2,702,169 in trading volume during the last 100 days, posting a change of +12.73%.
ABCL’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for ABCL stands at 0.07. Similarly, the long-term debt-to-equity ratio is also 0.06.
ABCL Stock Stochastic Average
Today’s raw stochastic average for AbCellera Biologics Inc over the last 50 days is 45.28%.This indicates a increase from the raw stochastic average of the past 20 days, which was 33.33%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 27.69% and 32.65%, respectively.
